Compare HP Inc (HPQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Sana Biotechnology Inc — how do they compare? HP Inc trades at $24.57 (market cap $22.15B), while Sana Biotechnology Inc trades at $3.19 (market cap $873.84M). The key difference: HP Inc is far larger — about 25.3× Sana Biotechnology Inc's market cap, and HP Inc pays a 4.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HPQ | SANA | |
|---|---|---|
Market Cap | $22.15B | $873.84M |
Sector | Technology | Health |
52-Week High | $29.35 | $5.92 |
52-Week Low | $18.20 | $2.68 |
Enterprise Value | $29.31B | $848.03M |
Dividend Yield | 4.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $24.395, down 1.79% on the day, with a bullish technical setup showing strong moving average signals. The stock offers attractive valuation metrics including a P/E of 9.2 and P/S of 0.41, with consistent earnings beats in recent quarters. Recent developments include strategic partnerships with OpenAI and Ferrari, positioning the company for AI PC growth. Cash flow trends show improvement with 2025 net cash flow of $460 million, though revenue has declined from 2022's $63B to $55.3B in 2025.
HPQ presents a value opportunity with strong dividend yield and improving cash flows, but faces headwinds from PC market volatility and competitive pressures. Analyst sentiment is mixed with 29% buy ratings versus 55% hold, suggesting cautious optimism. The stock's near-term performance will depend on AI PC adoption and execution of new strategic partnerships.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
